diabetestalk.net

Humalog Junior Kwikpen Ndc

0002-7714-59 Ndc Code | Humalog | Human Prescription Drug

0002-7714-59 Ndc Code | Humalog | Human Prescription Drug

Name of Company corresponding to the labeler code segment of the ProductNDC. Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the Document Type of the SPL submission for the listing. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. Sometimes called the generic name, this is usually the active ingredient(s) of the product. Also known as the trade name. It is the name of the product chosen by the labeler. A suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (XR) or sleep aid (PM). Although many companies follow certain naming conventions for suffices, there is no recognized standard. The following status describes submitted unfinished drugs, including the marketing categories of Active Pharmaceutical Ingredient (API), Drug for Further Processing, Bulk for Human Drug Compounding, and Bulk for Animal Drug Compounding. FDA does not review and approve unfinished products. Therefore, all products having "unfinished" status are considered unapproved. This is the assigned DEA Schedule number as reported by the labeler. Values are CI, CII, CIII, CIV, and CV. The labeler code, product code, and package code segments of the National Drug Code number, separated by hyphens. Asterisks are no longer used or included within the product and package code segments to indicate certain configurations of the NDC. 5 SYRINGE IN 1 CARTON (0002-7714-59) > 3 ML IN 1 SYRINGE (0002-7714-01) A description of the size and type of packaging in sentence form. Multilevel packages will hav Continue reading >>

Indications And Usage For Humalog

Indications And Usage For Humalog

Generic Name: insulin lispro Dosage Form: injection, solution Humalog is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. Humalog Dosage and Administration Important Administration Instructions Always check insulin labels before administration [see Warnings and Precautions (5.4)]. Inspect Humalog visually before use. It should appear clear and colorless. Do not use Humalog if particulate matter or coloration is seen. Do NOT mix Humalog U-100 with other insulins when administering using a continuous subcutaneous infusion pump. Do NOT transfer Humalog U-200 from the KwikPen to a syringe for administration [see Warnings and Precautions (5.4)]. Do NOT perform dose conversion when using any Humalog U-100 or U-200 KwikPens. The dose window shows the number of insulin units to be delivered and no conversion is needed. Humalog U-100 and U-200 KwikPens are designed to dial doses in increments of 1 unit. Humalog Junior KwikPen is designed to dial doses in 0.5 (1/2) unit increments. Do NOT mix Humalog U-200 with any other insulins. Do NOT administer Humalog U-200 using a continuous subcutaneous infusion pump (i.e., insulin pump). Do NOT administer Humalog U-200 intravenously. Route of Administration Subcutaneous Injection: Humalog U-100 or U-200 Administer the dose of Humalog U-100 or Humalog U-200 within fifteen minutes before a meal or immediately after a meal by injection into the subcutaneous tissue of the abdominal wall, thigh, upper arm, or buttocks. To reduce the risk of lipodystrophy, rotate the injection site within the same region from one injection to the next [see Adverse Reactions (6)]. Humalog administered by subcutaneous injection should generally be used in regimens with an intermediate- or lon Continue reading >>

Humalog® Junior Kwikpen® Now Available In The U.s. For People With Diabetes

Humalog® Junior Kwikpen® Now Available In The U.s. For People With Diabetes

INDIANAPOLIS, Oct. 4, 2017 /PRNewswire/ -- Humalog® Junior KwikPen® [insulin lispro injection 100 units/mL] is now available by prescription for the treatment of diabetes in the U.S. This innovation is the latest in the treatment and delivery options Eli Lilly and Company (NYSE: LLY) offers for people with type 1 or type 2 diabetes. Humalog Junior KwikPen is the only prefilled, disposable half-unit insulin pen. In June 2017, the U.S. Food and Drug Administration (FDA) approved Humalog Junior KwikPen for the treatment of diabetes. In September 2017, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for Humalog Junior KwikPen in the European Union and is pending final approval, expected later this year. "Learning how to inject insulin can be overwhelming, especially for newly diagnosed children and their caregivers. People often feel shock and anxiety, and may struggle with the reality of fitting diabetes into daily life," said Sherry Martin, M.D., vice president, Global Medical Affairs, Lilly Diabetes. "We hope to help take away some of the worries about the injection process with Humalog Junior KwikPen. Because it is prefilled, there are fewer steps for people to learn, and the half-unit increments make dosing more precise." Humalog Junior KwikPen, which is lighter and shorter than other half-unit insulin pens, provides an option for people who prefer a prefilled pen and need the precision of half-unit dosing, such as those with insulin sensitivity and some older adults for whom rounding to the nearest whole-unit dose is not adequate. Until now, the only way to deliver half units of insulin with a pen was through a reusable pen, which requires users to remove and load cartridges. Humalog Junior K Continue reading >>

April 2018 Formulary Changes: 2018 Medicare Part D Drug Lists Now Updated With 486 New Prescription Drugs - Part 2 Of 5 - Drugs Starting With The Letters D-h.

April 2018 Formulary Changes: 2018 Medicare Part D Drug Lists Now Updated With 486 New Prescription Drugs - Part 2 Of 5 - Drugs Starting With The Letters D-h.

April 2018 formulary changes: 2018 Medicare Part D drug lists now updated with 486 new prescription drugs - Part 2 of 5 - Drugs starting with the letters D-H. April 2018 formulary changes: 2018 Medicare Part D drug lists now updated with 486 new prescription drugs - Part 2 of 5 - Drugs starting with the letters D-H. The April, 2018 Medicare Part D plan formulary data (or drug list updates) includes the addition of 737 new National Drug Codes (NDCs) to the Medicare Part D program. These NDCs represent 486 different drugs, many with multiple strengths. There are so many new NDCs, that we have to split the list into 5 parts. This article will cover drugs starting with the letters D through H. Here are links to A-C , I-M , N-P , and Q-Z . Fifty-seven new NDC generic equivalents were added, including including DACTINOMYCIN [Cosmegen], DAPTOMYCIN [Cubicin], EFAVIRENZ [Sustiva], ELETRIPTAN HBR [Relpax], ESCITALOPRAM OXALATE [Lexapro],ESOMEPRAZOLE MAG [Nexium], ETHYNODIOL-ETH ESTRA [ZOVIA], ETODOLAC [LODINE], FENOFIBRATE [LIPOFEN], FENOFIBRIC ACID [TRILIPIX], FOSAMPRENAVIR [Lexiva], GLATIRAMER [Copaxone], Hepatitis B Surface Antigen Vaccine [Recombivax], Human-Bovine Reassortant Rotavirus Oral Vaccine [RotaTeq], HYDROXYPROGESTERONE [MAKENA], amongst others. See details in the chart below. As a reminder, the NDC uniquely identifies a particular manufacturer, drug-strength,and packaging combination. The NDC for your medication is often shownon your prescription bottle as an 11-digit code (see the charts below)or could be formatted as 00000-0000-00 where the first set of numbersidentifies the manufacturer, the second set of number identifies thedrug and strength, and the third set of numbers identifies thepackaging. New NDCs can be added to the Medicare Part D program for a numbe Continue reading >>

Preferred Drug List. Comprehensive. Updated April 2018

Preferred Drug List. Comprehensive. Updated April 2018

1 Comprehensive PREERRED DRUG LIST Updated April 2018 This ormulary is up to date through its date of publication, April Please notify IlliniCare Health at or (866) with any mistakes in the formulary. 2 Pharmacy Program IlliniCare Health is committed to providing the right drug coverage to our members. We work with providers and pharmacists to make sure we cover drugs used to treat many conditions and diseases. IlliniCare Health covers prescription and certain over-the-counter (OTC) medications when ordered by a network provider. The pharmacy program does not cover all medications. Some medications require prior authorization (PA) or have limitations on age, dosage, and maximum quantities. The IlliniCare Health pharmacy program covers members in the HealthChoice Illinois plan. illing a Prescription You can have your prescriptions filled at a network pharmacy. At the pharmacy, you will need to give the pharmacist your prescription and your ID card. You can find a pharmacy that is in the IlliniCare Health network by using the ind a Provider tool on If you need help finding a pharmacy near you, call us at (toll-free)/ TTY: 771. There is no cost for covered drugs. If your medication is not on the preferred drug list or is on the preferred drug list but has limitations, you can: 1. Speak with your doctor about switching to a similar medication that is on the preferred drug list. 2. Request a prior authorization, or speak to your doctor about submitting a prior authorization for you. You or your doctor may do this by submitting the medication prior authorization form, found on Generic s Generic drugs have the same active ingredient and work the same as brand name drugs. When generic drugs are available, the brand name drug will not be covered without prior authorization. Spe Continue reading >>

Drug Information On Humalog - Eli Lilly And Company | Pharmaguru.com

Drug Information On Humalog - Eli Lilly And Company | Pharmaguru.com

Sections or subsections omitted from the full prescribing information are not listed. HUMALOG is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. 2.1 Important Administration Instructions Always check insulin labels before administration [see Warnings and Precautions ( 5.4 )]. Inspect HUMALOG visually before use. It should appear clear and colorless. Do not use HUMALOG if particulate matter or coloration is seen. Do NOT mix HUMALOG U-100 with other insulins when administering using a continuous subcutaneous infusion pump. Do NOT transfer HUMALOG U-200 from the KwikPen to a syringe for administration [see Warnings and Precautions ( 5.4 )]. Do NOT perform dose conversion when using any HUMALOG U-100 or U-200 KwikPens. The dose window shows the number of insulin units to be delivered and no conversion is needed. HUMALOG U-100 and U-200 KwikPens are designed to dial doses in increments of 1 unit. HUMALOG Junior KwikPen is designed to dial doses in 0.5 (1/2) unit increments. Do NOT mix HUMALOG U-200 with any other insulins. Do NOT administer HUMALOG U-200 using a continuous subcutaneous infusion pump (i.e., insulin pump). Do NOT administer HUMALOG U-200 intravenously. Subcutaneous Injection: HUMALOG U-100 or U-200 Administer the dose of HUMALOG U-100 or HUMALOG U-200 within fifteen minutes before a meal or immediately after a meal by injection into the subcutaneous tissue of the abdominal wall, thigh, upper arm, or buttocks. To reduce the risk of lipodystrophy, rotate the injection site within the same region from one injection to the next [see Adverse Reactions ( 6 )]. HUMALOG administered by subcutaneous injection should generally be used in regimens with an intermediate- or long-acting insulin. Conti Continue reading >>

Reference Bd Needles Reference To Bd Ultra-fineâ„¢ Pen Needles

Reference Bd Needles Reference To Bd Ultra-fineâ„¢ Pen Needles

Drug Manufacturer Pen Name Drug Drug NDC Number Place Where Drug Manufacturers Sanofi-Aventis Apidra® SoloStar® Apidra® 0088-2502-05 Package Insert Patient Instructions for use Patient Toll Free Phone Number “SoloStar® is compatible with all pen needles from Becton Dickinson and Company†Lantus® SoloStar® Lantus® 0088-2219-05 Package Insert User Manual, Device Page, Website “ BD Ultra-Fine™ needles to be used in conjunction with SoloStar® and OptiClik® are sold separately and are manufactured by BD.†“ BD Ultra-Fine™ needles are compatible with SoloStar® . These are sold separately and are manufactured by BD.†Amylin Pharmaceuticals & Eli Lilly and Company Byetta® Byetta® 66780-0212-01 66780-0210-07 Amylin Pharmaceuticals SymlinPen® 60 & 120 Symlin® 66780-115-02 66780-121-02 Eli Lilly and Company HumaPen® LUXURA™ HD Humalog® 3mL 0002-7516-59 User Manual, Website “ HumaPen® LUXURA™ HD is suitable for use with Becton, Dickinson and Company pen needles.†Humalog® KwikPen™ Humalog® Humalog® Mix 75/25® Humalog® Mix 50/50 0002-8799-59 0002-8797-59 0002-8798-59 User Manual, Brochures, Prescribing Card “ When prescribing KwikPen™ prefilled with the Humalog brand of insulins you will need to write a separate prescription for BD needles.†Humulin® Pen Humulin® N Humulin® 70/30 0002-8730-59 0002-8770-59 User Manual, Website “ This device is suitable for use with Becton, Dickinson and Company’s insulin pen needles.†Novo Nordisk, Inc. Victoza® Victoza® N/A NovoLog® Mix FlexPen® NovoLog® Mix 70/30 N/A NovoPen® Junior Novo Nordisk PenFill 3ml N/A Novo Pen® 3 Novo Nordisk PenFill 3ml N/A L Continue reading >>

Ndc 0002-7714 Humalog Junior Kwikpen

Ndc 0002-7714 Humalog Junior Kwikpen

HUMALOG is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. 2.1 Important Administration Instructions Always check insulin labels before administration [see Warnings and Precautions (5.4)].Inspect HUMALOG visually before use. It should appear clear and colorless. Do not use HUMALOG if particulate matter or coloration is seen.Do NOT mix HUMALOG U-100 with other insulins when administering using a continuous subcutaneous infusion pump.Do NOT transfer HUMALOG U-200 from the KwikPen to a syringe for administration [see Warnings and Precautions (5.4)].Do NOT perform dose conversion when using either the HUMALOG U-100 or U-200 KwikPens. The dose window shows the number of insulin units to be delivered and no conversion is needed.Do NOT mix HUMALOG U-200 with any other insulins.Do NOT administer HUMALOG U-200 using a continuous subcutaneous infusion pump (i.e., insulin pump).Do NOT administer HUMALOG U-200 intravenously. Subcutaneous Injection: HUMALOG U-100 or U-200Administer the dose of HUMALOG U-100 or HUMALOG U-200 within fifteen minutes before a meal or immediately after a meal by injection into the subcutaneous tissue of the abdominal wall, thigh, upper arm, or buttocks. To reduce the risk of lipodystrophy, rotate the injection site within the same region from one injection to the next [see Adverse Reactions (6)]. HUMALOG administered by subcutaneous injection should generally be used in regimens with an intermediate- or long-acting insulin. Continuous Subcutaneous Infusion (Insulin Pump): HUMALOG U-100 ONLYDo NOT administer HUMALOG U-200 using a continuous subcutaneous infusion pump. Administer HUMALOG U-100 by continuous subcutaneous infusion into the subcutaneous tissue of the abdominal wall. Rot Continue reading >>

Sanofi-aventis

Sanofi-aventis

Drug Manufacturer Pen Name Drug Drug NDC Number Do BD Pen Needles Fit?* Sample Bag of BD Pen Needles in Drug Starter Kits Place Where Drug Manufacturers Reference BD Needles Reference to BD Ultra-Fineâ„¢ Pen Needles Sanofi-Aventis Apidra® SoloStar® Apidra® 0088-2502-05 Yes N/A Package Insert Patient Instructions for use Patient Toll Free Phone Number "SoloStar® is compatible with all pen needles from Becton Dickinson and Company" Lantus® SoloStar® Lantus® 0088-2220-60 Yes N/A Package Insert User Manual, Device Page, Website "BD Ultra-Fineâ„¢ needles to be used in conjunction with SoloStar® and OptiClik® are sold separately and are manufactured by BD." "BD Ultra-Fineâ„¢ needles are compatible with SoloStar® . These are sold separately and are manufactured by BD." OptiClik® for Apidra® Apidra® 3mL Cartridge 0088-2500-52 Yes Yes User Manual Patient Checklist "Needles are available from BD Consumer Healthcare." "Prescription for BD pen needles." OptiClik® for Lantus® Lantus® 3mL Cartridge 0088-2220-52 Yes Yes User Manual, Patient Checklist, Lantus® Package Insert "Needles are available in different lengths and gauges from BD Consumer Healthcare." Amylin Pharmaceuticals & Eli Lilly and Company Byetta® Byetta® 66780-0210-07 66780-0210-08 Yes Yes Amylin Pharmaceuticals SymlinPenâ„¢ 60 & 120 Symlin ® 66780-155-02 66780-121-02 Yes Yes, 5mm Eli Lilly and Company HumaPen® Memoirâ„¢ Humalog® 3mL Cartridge 0002-7516-59 Yes Yes, 8mm User Manual, Website "HumaPen ® MEMOIRâ„¢ is suitable for use with Becton, Dickinson and Company insulin pen needles." HumaPen® LUXURAâ„¢ HD Humalog® 3mL Cartridge 0002-7516-59 Yes N/A, No Starter Kit Offered User Manual, Website "HumaPen ® LUXURAâ Continue reading >>

Ndc Code 0002-7714-59 Humalog Junior Kwikpen

Ndc Code 0002-7714-59 Humalog Junior Kwikpen

All contents of this website are provided on an "as is" and "as available" basis without warranty of any kind. The contents of the National Drug Codes List website are provided for educational purposes only and are not intended in any way as medical advice, medical diagnosis or treatment. Reliance on any information provided by the National Drug Codes List website or other visitors to this website is solely at your own risk. Many of Over the Counter drugs are not reviewed by the FDA but they might be marketed to the public if the product complies with the applicable rules and regulations. The information in this website is intended for healthcare providers and consumers in the United States. The absence of a warning or notice for a given drug or drug combination is not indication that the drug or drug combination are safe, appropriate or effective for any given patient. If you have questions or concerns about the substances you are taking, check with your healthcare provider. If you think you may have a medical emergency, please call your doctor or 911 immediately. Continue reading >>

July 2018 Ndc - Hcpcs Crosswalk

July 2018 Ndc - Hcpcs Crosswalk

Effective July 1, 2018 through September 30, 2018 Coagulation Factor IX, Recombinant (Ixinity) Coagulation Factor IX, Recombinant (Ixinity) Coagulation Factor IX, Recombinant (Ixinity) Coagulation Factor IX, Recombinant (Ixinity) Coagulation Factor IX, Recombinant (Ixinity) Coagulation Factor IX, Recombinant (Ixinity) Coagulation Factor IX, Recombinant (Ixinity) Coagulation Factor IX, Recombinant (Ixinity) METRONIDAZOLE 500 MG INJ USP LIFECARE 100ML FILL Olanzapine short acting intramuscular injection Olanzapine short acting intramuscular injection Olanzapine short acting intramuscular injection Sodium Chloride, Hypertonic (3% - 5% infusion) Sodium Chloride, Hypertonic (3% - 5% infusion) Sodium Chloride, Hypertonic (3% - 5% infusion) Sodium Chloride, Hypertonic (3% - 5% infusion) HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS , America's Health Insurance Plans , and Blue Cross and Blue Shield Association ). CPT is a registered trademark of the American Medical Association (AMA). All rights reserved. Continue reading >>

Humalog Junior Kwikpen Ndc

Humalog Junior Kwikpen Ndc

You were looking forHumalog Junior Kwikpen Ndc? You most likely will find some useful information in this article, come have a quick look! Taking insulin or other diabetes medicines is typically part of treating diabetes Together with healthy food options and physical activity, medicine can help you manage the disease. Some other treatment options are likewise readily available. What medications might I take for diabetes? The medication you take will differ by your type of diabetes and how well the medication controls your blood glucose levels, likewise called blood sugar. Other factors, such as your other health conditions, medication expenses, and your daily schedule may contribute in exactly what diabetes medication you take. Some people with type 2 diabetes can handle their disease by making healthy food choices and being more physically active. Many people with type 2 diabetes requirement diabetes medications as well. These medicines might include diabetes pills or medicines you inject under your skin, such as insulin. In time, you may need more than one diabetes medicine to control your blood sugar. Even if you do not take insulin, you may require it at unique times, such as throughout pregnancy or if you are in the medical facility. If you have gestational diabetes, you must initially try to manage your blood sugar level by making healthy food choices and getting regular physical activity. If you cannot reach your blood glucose target, your healthcare team will talk with you about diabetes medicines, such as insulin or the diabetes pill metformin, that might be safe for you to take throughout pregnancy. Your healthcare team may begin you on diabetes medications right now if your blood glucose is very high. No matter what kind of diabetes you have, taking diabete Continue reading >>

Why Humalog U-100 Kwikpen Might Be Right For Your Patients

Why Humalog U-100 Kwikpen Might Be Right For Your Patients

Humalog KwikPen is a small, lightweight, prefilled insulin pen for patients with type 2 or type 1 diabetes who want a portable device. Humalog KwikPen should not be refrigerated after first use and can be taken just about anywhere. Patients can carry it in their purse, backpack, or pocket because it’s the size of a marker. Remind your patients to always carry an extra pen. In-use Humalog KwikPen should be stored at room temperature, below 86°F (30°C). Humalog KwikPen must be used within 28 days or be discarded, even if it still contains Humalog. Humalog U-100 KwikPen can be an easy-to-use, easy-to-inject prefilled pen option*14 Easy to set the dose*14 Easy to see the numbers*14 Easy to dial up and back down for dose selection*14 Easy to dispense maximum dose of 60 units*14 Allows patients or caregivers to discreetly deliver insulin To help patients and their caregivers learn how to inject using Humalog KwikPen, please click to access the Humalog U-100 KwikPen Instructions for Use. *Humalog KwikPen Design Validation User Study included adult male and female participants with type 1 and type 2 diabetes. Of the total 150 study participants, 56 were insulin-naïve, 42 were currently administering insulin with a vial and syringe, and 52 were experienced insulin pen users. Pen needles for use with Humalog KwikPen Humalog KwikPen is suitable for use with Becton Dickinson (BD) needles (sold separately and may require a separate prescription). BD offers a comprehensive line of advanced protection products. For more information about BD pen needles, visit the BD Diabetes website for healthcare professionals. Pens and needles are for single-patient use only and should not be shared, even in healthcare facilities, as infection or disease can be spread from one person to another Continue reading >>

Novolog® (insulin Aspart Injection) 100 U/ml Indications And Usage

Novolog® (insulin Aspart Injection) 100 U/ml Indications And Usage

NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Patients using NovoLog® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. NovoLog® (insulin aspart injection) 100 U/mL is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Patients using NovoLog® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. Hypoglycemia is the most common adverse effect of insulin therapy. The timing of hypoglycemia may reflect the time-action profile of the insulin formulation. Glucose monitoring is re Continue reading >>

0002-7714-59 Ndc Code | Humalog | Human Prescription Drug

0002-7714-59 Ndc Code | Humalog | Human Prescription Drug

Name of Company corresponding to the labeler code segment of the ProductNDC. Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the Document Type of the SPL submission for the listing. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. Sometimes called the generic name, this is usually the active ingredient(s) of the product. Also known as the trade name. It is the name of the product chosen by the labeler. A suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (XR) or sleep aid (PM). Although many companies follow certain naming conventions for suffices, there is no recognized standard. The following status describes submitted unfinished drugs, including the marketing categories of Active Pharmaceutical Ingredient (API), Drug for Further Processing, Bulk for Human Drug Compounding, and Bulk for Animal Drug Compounding. FDA does not review and approve unfinished products. Therefore, all products having "unfinished" status are considered unapproved. This is the assigned DEA Schedule number as reported by the labeler. Values are CI, CII, CIII, CIV, and CV. The labeler code, product code, and package code segments of the National Drug Code number, separated by hyphens. Asterisks are no longer used or included within the product and package code segments to indicate certain configurations of the NDC. 5 SYRINGE IN 1 CARTON (0002-7714-59) > 3 ML IN 1 SYRINGE (0002-7714-01) A description of the size and type of packaging in sentence form. Multilevel packages will hav Continue reading >>

More in diabetes